## Berta MarÃ-a Pascual Sedano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6844791/publications.pdf

Version: 2024-02-01

87 papers

5,393 citations

94269 37 h-index 71 g-index

93 all docs 93
docs citations

93 times ranked 5751 citing authors

#	Article	IF	Citations
1	Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson's disease mild cognitive impairment. Brain Imaging and Behavior, 2022, 16, 761-772.	1.1	4
2	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. Journal of the Neurological Sciences, 2022, 434, 120148.	0.3	13
3	Manejo de la enfermedad de Parkinson y otros trastornos del movimiento en mujeres en edad fértil: Parte 1. NeurologÃa, 2021, 36, 149-158.	0.3	1
4	Depression is Associated with Impulse-compulsive Behaviors in Parkinson's disease. Journal of Affective Disorders, 2021, 280, 77-89.	2.0	9
5	Manejo de la enfermedad de Parkinson y otros trastornos del movimiento en mujeres en edad fértil: parte 2. NeurologÃa, 2021, 36, 159-168.	0.3	1
6	Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. Journal of Neurology, 2021, 268, 3400-3408.	1.8	12
7	Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2021, 85, 63-68.	1.1	6
8	InÂvivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. Parkinsonism and Related Disorders, 2021, 88, 68-75.	1.1	16
9	Predictors of clinically significant quality of life impairment in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 118.	2.5	17
10	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. BMC Neurology, 2021, 21, 477.	0.8	7
11	Preservation of brain metabolism in recently diagnosed Parkinson's impulse control disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2165-2174.	3.3	5
12	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. Scientific Reports, 2020, 10, 16893.	1.6	6
13	Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1611-1620.	1.5	15
14	Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression. Journal of the Neurological Sciences, 2020, 418, 117109.	0.3	11
15	The Free and Cued Selective Reminding Test in Parkinson's Disease Mild Cognitive Impairment: Discriminative Accuracy and Neural Correlates. Frontiers in Neurology, 2020, 11, 240.	1.1	6
16	Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa. Journal of Neurology, 2020, 267, 3400-3410.	1.8	3
17	Measuring impulsivity in Parkinson's disease: a correlational and structural neuroimaging study using different tests. European Journal of Neurology, 2020, 27, 1478-1486.	1.7	6
18	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. Neurological Sciences, 2020, 41, 2883-2892.	0.9	13

#	Article	IF	CITATIONS
19	Isolated Propriospinal Myoclonus as a Presentation of Cervical Myelopathy. Tremor and Other Hyperkinetic Movements, 2020, 8, 598.	1.1	3
20	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. Parkinsonism and Related Disorders, 2019, 66, 151-157.	1.1	71
21	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. Journal of Neural Transmission, 2019, 126, 1599-1608.	1.4	11
22	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€6pecific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	2.2	47
23	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	2.2	66
	<scp>COPPADIS</scp> â€2015 ( <scp>CO</scp> hort of Patients with PArkinson's <scp>DI</scp> sease in) Tj ETQc	η0 0 0 rgB <sup>-</sup>	Γ/Overlock I
24	1000 subjects included. Results from the baseline evaluation. European Journal of Neurology, 2019, 26, 1399-1407.	1.7	32
25	A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment. Human Brain Mapping, 2019, 40, 3233-3242.	1.9	38
26	Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease. Movement Disorders, 2019, 34, 78-86.	2.2	58
27	Perampanel, a new hope for Essential tremor: An open label trial. Parkinsonism and Related Disorders, 2019, 60, 171-172.	1.1	13
28	Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. Parkinson's Disease, 2018, 2018, 1-5.	0.6	22
29	Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity. Frontiers in Psychiatry, 2018, 9, 465.	1.3	24
30	Isolated Propriospinal Myoclonus as a Presentation of Cervical Myelopathy. Tremor and Other Hyperkinetic Movements, 2018, 8, 598.	1.1	4
31	Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: a prospective observational study. Journal of Translational Medicine, 2017, 15, 43.	1.8	19
32	Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients. Movement Disorders, 2017, 32, 165-169.	2.2	19
33	Minor hallucinations occur in drugâ€naive Parkinson's disease patients, even from the premotor phase. Movement Disorders, 2016, 31, 45-52.	2.2	167
34	COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. BMC Neurology, 2016, 16, 26.	0.8	66
35	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 175-180.	1.1	13
36	Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. Parkinsonism and Related Disorders, 2016, 25, 58-64.	1.1	122

#	Article	IF	Citations
37	Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism and Related Disorders, 2015, 21, 871-876.	1.1	79
38	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the diseaseâ€. Human Molecular Genetics, 2015, 24, 2023-2034.	1.4	45
39	Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. Drugs and Aging, 2015, 32, 401-407.	1.3	18
40	Severity stages in essential tremor: a long-term retrospective study using the glass scale. Tremor and Other Hyperkinetic Movements, 2015, 5, 299.	1.1	13
41	Apathy in Parkinson's Disease: Neurophysiological Evidence of Impaired Incentive Processing. Journal of Neuroscience, 2014, 34, 5918-5926.	1.7	55
42	Transcranial Direct Current Stimulation of the Cerebellum in Essential Tremor: A Controlled Study. Brain Stimulation, 2014, 7, 491-492.	0.7	33
43	Parkinson's diseaseâ€cognitive rating scale: Psychometrics for mild cognitive impairment. Movement Disorders, 2013, 28, 1376-1383.	2.2	58
44	Measuring functional impact of cognitive impairment: Validation of the Parkinson's Disease Cognitive Functional Rating Scale. Parkinsonism and Related Disorders, 2013, 19, 812-817.	1.1	69
45	Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson's Disease. PLoS ONE, 2013, 8, e54980.	1.1	112
46	Spectroscopic Changes Associated with Mild Cognitive Impairment and Dementia in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2012, 34, 312-318.	0.7	24
47	Gaba and serotonin molecular neuroimaging in essential tremor: A clinical correlation study. Parkinsonism and Related Disorders, 2012, 18, 876-880.	1.1	50
48	Impact of apathy on healthâ€related quality of life in recently diagnosed Parkinson's disease: The ANIMO study. Movement Disorders, 2012, 27, 211-218.	2.2	105
49	Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Movement Disorders, 2012, 27, 393-399.	2.2	144
50	Impulse control disorders and dopaminergic treatments in Parkinson's disease. Revue Neurologique, 2011, 167, 827-832.	0.6	6
51	Lacosamide, another therapeutic failure in essential tremor: An openâ€label trial. Movement Disorders, 2011, 26, 183-184.	2.2	5
52	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.9	125
53	Using the WHOQOL-DIS to Measure Quality of Life in Persons with Physical Disabilities Caused by Neurodegenerative Disorders. Neurodegenerative Diseases, 2011, 8, 178-186.	0.8	21
54	PDDâ€Short Screen: A brief cognitive test for screening dementia in Parkinson's disease. Movement Disorders, 2010, 25, 440-446.	2.2	31

#	Article	IF	Citations
55	Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Movement Disorders, 2010, 25, 2785-2791.	2.2	70
56	Facial Emotion Recognition Impairment in Patients with Parkinson's Disease and Isolated Apathy. Parkinson's Disease, 2010, 2010, 1-5.	0.6	32
57	Longâ€ŧerm effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Movement Disorders, 2009, 24, 1154-1161.	2.2	140
58	Tremor dominant parkinsonism: Clinical description and <i>LRRK2</i> mutation screening. Movement Disorders, 2008, 23, 518-523.	2.2	46
59	A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Movement Disorders, 2008, 23, 443-448.	2.2	41
60	Parkinson's diseaseâ€cognitive rating scale: A new cognitive scale specific for Parkinson's disease. Movement Disorders, 2008, 23, 998-1005.	2.2	264
61	Cutâ€off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Movement Disorders, 2008, 23, 1546-1550.	2.2	117
62	Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Movement Disorders, 2008, 23, 1889-1896.	2.2	190
63	Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. European Journal of Neurology, 2008, 15, 953-959.	1.7	42
64	Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism and Related Disorders, 2008, 14, 443-445.	1.1	29
65	Levodopa and executive performance in Parkinson's disease: A randomized study. Journal of the International Neuropsychological Society, 2008, 14, 832-841.	1.2	41
66	Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study. Movement Disorders, 2007, 22, 62-67.	2.2	67
67	Controlled study of decision-making and cognitive impairment in Parkinson's disease. Movement Disorders, 2007, 22, 1430-1435.	2.2	116
68	"Prodromic―tremor: Prevalence and clinical correlates. Movement Disorders, 2007, 22, 1203-1204.	2.2	1
69	Effect of amantadine in essential tremor: A randomized, placebo-controlled trial. Movement Disorders, 2006, 21, 441-445.	2.2	19
70	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain, 2005, 128, 2240-2249.	3.7	963
71	Semantic Knowledge of Famous People in Mild Cognitive Impairment and Progression to Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2004, 17, 188-195.	0.7	74
72	Routine Neurophysiologic Tremor Analysis as a Diagnostic Tool for Essential Tremor: A Prospective Study. Journal of Clinical Neurophysiology, 2004, 21, 446-450.	0.9	56

#	Article	IF	CITATIONS
73	Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease. Journal of Neurology, 2003, 250, 917-923.	1.8	103
74	Diagnostic potential of acoustic startle reflex, acoustic blink reflex, and electro-oculography in progressive supranuclear palsy: A prospective study. Movement Disorders, 2003, 18, 1273-1279.	2.2	27
75	Mania following deep brain stimulation for Parkinson's disease. Neurology, 2002, 59, 1421-1424.	1.5	277
76	Transcranial Magnetic Stimulation of the Cerebellum in Essential Tremor. Archives of Neurology, 2002, 59, 413.	4.9	104
77	A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease. Clinical Neuropharmacology, 2002, 25, 25-31.	0.2	39
78	Motor Circuitry Re-organization After Pallidotomy in Parkinson Disease. Journal of Clinical Neurophysiology, 2002, 19, 553-561.	0.9	10
79	Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders. Movement Disorders, 2001, 16, 1098-1104.	2.2	42
80	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients. Movement Disorders, 2000, 15, 613-626.	2.2	148
81	Bilateral pallidal stimulation for cervical dystonia: Dissociated pain and motor improvement. Neurology, 2000, 55, 1754-1755.	1.5	81
82	Abnormalities of the acoustic startle reflex and reaction time in Gilles de la Tourette syndrome. Clinical Neurophysiology, 2000, 111, 1366-1371.	0.7	25
83	Prospective Study of New-Onset Seizures in Patients With Human Immunodeficiency Virus Infection. Archives of Neurology, 1999, 56, 609.	4.9	61
84	A Randomized Placebo-Controlled Comparative Trial of Gabapentin and Propranolol in Essential Tremor. Archives of Neurology, 1999, 56, 475.	4.9	205
85	Horner's syndrome due to giant cell arteritis. Neuro-Ophthalmology, 1998, 20, 75-77.	0.4	2
86	Progressive Posterior Cerebral Artery Infarction Mimicking Middle Cerebral Artery Infarction with Transtentorial Herniation. Cerebrovascular Diseases, 1996, 6, 251-253.	0.8	1
87	A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease. Frontiers in Neurology, 0, 13, .	1.1	5